Show simple item record

dc.contributor.authorConnell, Claire M.
dc.contributor.authorBrais, Rebecca
dc.contributor.authorWhitaker, Hayley
dc.contributor.authorUpponi, Sara
dc.contributor.authorBeh, Ian
dc.contributor.authorRisdall, Jane
dc.contributor.authorCorrie, Pippa
dc.contributor.authorJanowitz, Tobias
dc.contributor.authorJodrell, Duncan I.
dc.date.accessioned2021-01-14T16:19:45Z
dc.date.available2021-01-14T16:19:45Z
dc.date.issued2020-01-15
dc.date.submitted2019-03-22
dc.identifier.others12885-020-6516-1
dc.identifier.other6516
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/316184
dc.descriptionFunder: Cambridge Experimental Medicine Initiative
dc.descriptionFunder: Cancer Research United Kingdom
dc.description.abstractAbstract: Background: Pancreatic adenosquamous carcinoma has a poor prognosis, with limited prospective trial data to guide optimal treatment. The potential impact of drug metabolism on the treatment response of patients with pancreatic adenosquamous carcinoma is largely unknown. Case presentation: We describe the case of a 51 year old woman with pancreatic adenosquamous carcinoma who, following surgical resection, experienced early disease relapse during adjuvant gemcitabine therapy. Paradoxically, this was followed by an exceptional response to capecitabine therapy lasting 34.6 months. Strong expression of cytidine deaminase was detected within the tumour. Conclusions: This case study demonstrates that early relapse during adjuvant chemotherapy for pancreatic adenosquamous carcinoma may be compatible with a subsequent exceptional response to second line chemotherapy, an important observation given the poor overall prognosis of patients with adenosquamous carcinoma. Cytidine deaminase is predicted to inactivate gemcitabine and, conversely, catalyze capecitabine activation. We discuss strong intra-tumoural expression of cytidine deaminase as a potential mechanism to explain this patient’s disparate responses to gemcitabine and capecitabine therapy, and highlight the benefit that may be gained from considering similar determinants of response to chemotherapy in clinical practice.
dc.languageen
dc.publisherBioMed Central
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectCase Report
dc.subjectMedical and radiation oncology
dc.subjectCytidine deaminase
dc.subjectDrug metabolism
dc.subjectGemcitabine
dc.subjectPancreatic adenosquamous carcinoma
dc.titleEarly relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report
dc.typeArticle
dc.date.updated2021-01-14T16:19:44Z
prism.issueIdentifier1
prism.publicationNameBMC Cancer
prism.volume20
dc.identifier.doi10.17863/CAM.63292
dcterms.dateAccepted2020-01-06
rioxxterms.versionofrecord10.1186/s12885-020-6516-1
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidJodrell, Duncan I. [0000-0001-9360-1670]
dc.identifier.eissn1471-2407


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)